Compare AMS & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | COCP |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 15.3M |
| IPO Year | N/A | N/A |
| Metric | AMS | COCP |
|---|---|---|
| Price | $2.14 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 7.7K | ★ 103.2K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,423,000.00 | N/A |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.84 | N/A |
| 52 Week Low | $2.01 | $0.90 |
| 52 Week High | $3.21 | $2.67 |
| Indicator | AMS | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 48.68 |
| Support Level | $2.08 | $1.00 |
| Resistance Level | $2.20 | $1.19 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 59.26 | 22.68 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).